Reflect Scientific (RSCF) AI Stock Analysis

• Market Cap: $4.50M
• Dividend Yield: N/A
• Average Volume (3M): 66.91K
• Price to Earnings (P/E): 19.7
• Beta (1Y): 1.39
• Revenue Growth: 43.30%
• EPS Growth: N/A
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 52
• Industry: Medical - Instruments & Supplies
• EPS (TTM): <0.01
• Shares Outstanding: 85,664,085
• 10 Day Avg. Volume: 135,809
• 30 Day Avg. Volume: 66,906
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 3.15
• Enterprise Value/Gross Profit: 5.59
• Enterprise Value/Ebitda: 14.98
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Reflect Scientific faces significant risks due to its weak financial performance, particularly in cash flow and profitability. However, the technical indicators suggest some short-term positive momentum. Valuation remains a concern with a negative P/E ratio, reflecting the company's current financial struggles.

Reflect Scientific Business Overview & Revenue Model

Company Description

Reflect Scientific, Inc. designs, develops, and sells scientific equipment for the life science and manufacturing industries worldwide. The company offers Cryometrix ultra low temperature and blast freezers, which are used to store various products, including blood and cancer vaccines. It also provides laboratory consumables and disposables, such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, and graphite and vespel/graphite sealing components for use by original equipment manufacturers in the field of gas/liquid chromatography in the chemical analysis industries. In addition, the company offers solvent chillers and refrigerated transportation products. It serves hospitals diagnostic laboratories, pharmaceutical and biotech companies, universities, government, and private sector research facilities, as well as cold chain management, chemical, and industrial companies. Reflect Scientific, Inc. is based in Orem, Utah.

How the Company Makes Money

Reflect Scientific generates revenue primarily through the sale of its specialized refrigeration and cryogenic cooling systems. These products cater to a niche market that requires precise temperature control for research, storage, and transportation. Key revenue streams include direct sales to laboratories, pharmaceutical companies, and logistics firms that need to maintain the integrity of temperature-sensitive materials. In addition to product sales, Reflect Scientific may engage in strategic partnerships or collaborations with other companies in related sectors to enhance its offerings and expand its market reach. Service contracts and maintenance agreements for its equipment could also contribute to its revenue, ensuring recurring income from existing customers.

Reflect Scientific Financial Statement Overview

Summary

Reflect Scientific exhibits a mixed financial performance. The strong balance sheet with low leverage is offset by significant challenges in profitability and cash management, as highlighted by the income statement and cash flow issues.

Income Statement

Reflect Scientific has seen significant fluctuations in its revenue and profitability. The TTM shows a noticeable increase in revenue from the previous year, but the company is still operating at a net loss. Gross profit margin remains relatively healthy at 40.1% for TTM, though net profit margin is negative, indicating potential issues in cost management or operational efficiency.

Balance Sheet

The company maintains a solid equity ratio of 88.9% and a low debt-to-equity ratio of 0.09, indicating strong financial stability and low leverage. However, a decline in total assets and stockholders' equity compared to previous years might suggest challenges in asset growth or capital retention.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flow in the TTM, reflecting potential liquidity issues. The operating cash flow to net income ratio is unfavorable, indicating struggles in converting profits into cash.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.47M	1.08M	2.04M	2.81M	2.79M	1.61M
Gross Profit	828.57K	596.42K	1.22M	1.93M	1.72M	991.64K
EBITDA	309.24K	-405.78K	146.32K	996.22K	723.35K	-190.85K
Net Income	274.85K	-459.03K	89.40K	939.07K	660.12K	-196.34K
Balance Sheet
Total Assets	2.34M	2.67M	2.45M	2.48M	1.68M	1.08M
Cash, Cash Equivalents and Short-Term Investments	1.08M	1.28M	1.38M	1.47M	642.54K	555.16K
Total Debt	160.99K	242.64K	57.39K	113.84K	279.36K	67.61K
Total Liabilities	217.61K	776.33K	149.59K	299.24K	463.31K	525.75K
Stockholders Equity	2.12M	1.89M	2.30M	2.18M	1.21M	553.03K
Cash Flow
Free Cash Flow	-8.16K	-103.98K	-92.00K	831.38K	-25.22K	335.87K
Operating Cash Flow	-8.16K	-103.98K	-92.00K	831.38K	-25.22K	335.87K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	0.00	2.25K	27.50K	112.60K	-1.14K

Reflect Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RSCF, the sentiment is Positive. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and above the 200-day MA of 0.05, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.75 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RSCF.

Reflect Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	71 Outperform	$12.06M	1.10	7.10%	―	-0.19%	-18.41%
NEPH	65 Neutral	$41.66M	35.23	15.14%	―	21.16%	―
Sector *	51 Neutral	$7.93B	-0.32	-43.43%	2.21%	22.30%	-1.88%
HBIO	50 Neutral	$20.24M	―	-138.36%	―	-12.24%	-427.45%
RSCF	47 Neutral	$4.50M	19.67	12.92%	―	43.30%	―
FEMY	44 Neutral	$16.55M	―	-329.45%	―	98.61%	-1.98%
POAI	39 Underperform	$10.47M	―	-708.73%	―	-38.79%	58.27%